MTOR activation in immature cells of primary nasopharyngeal carcinoma and anti-tumor effect of rapamycin in vitro and in vivo

Cancer Letters

Volumn 341, Issue 2, 2013, Pages 186-194

  Yang, Chunguang ^a   Peng, Jianhua ^a   Jiang, WenJing ^a   Zhang, Yue ^a   Chen, Xiaoyun ^a   Wu, Xianmin ^a   Zhu, Yi ^a   Zhang, Huxiang ^a   Chen, Jianfu ^a   Wang, Jixian ^c   Cho, William C S ^b   Jin, Kunlin ^a,c  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^c UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Cancer stem cells; MTOR signaling; Nasopharyngeal carcinoma; Rapamycin

Indexed keywords

CD133 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN S6; RAPAMYCIN; TRANSCRIPTION FACTOR SOX2; ANTINEOPLASTIC ANTIBIOTIC; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; MTOR PROTEIN, HUMAN; PEPTIDE; POU5F1 PROTEIN, HUMAN; SOX2 PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TRANSCRIPTION FACTOR SOX;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CANCER INHIBITION; CANCER STEM CELL; CLINICAL ARTICLE; CONTROLLED STUDY; EMBRYONIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; ENZYME ACTIVATION; ENZYMOLOGY; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NUDE MOUSE; PATHOLOGY; TIME; TUMOR CELL CULTURE; TUMOR VOLUME; WESTERN BLOTTING;

MAMMALIA; MUS MUSCULUS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, CD; BLOTTING, WESTERN; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; PEPTIDES; SIGNAL TRANSDUCTION; SIROLIMUS; SOXB1 TRANSCRIPTION FACTORS; TIME FACTORS; TOR SERINE-THREONINE KINASES; TUMOR BURDEN; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84887178635     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.08.004     Document Type: Article

References (39)

1. Cho W.C. Nasopharyngeal carcinoma: molecular biomarker discovery and progress. Mol. Cancer 2007, 6:1.
2. Colaco R.J., Betts G., Donne A., Swindell R., Yap B.K., Sykes A.J., Slevin N.J., Homer J.J., Lee L.W. Nasopharyngeal carcinoma: a retrospective review of demographics, treatment and patient outcome in a single centre. Clin. Oncol. (R Coll. Radiol.) 2013, 25:171-177.
3. Wei W.I., Sham J.S. Nasopharyngeal carcinoma. Lancet 2005, 365:2041-2054.
4. Young L.S., Rickinson A.B. Epstein-Barr virus: 40years on. Nat. Rev. Cancer 2004, 4:757-768.
5. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100:3983-3988.
6. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D., Dirks P.B. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
7. Wang J., Guo L.P., Chen L.Z., Zeng Y.X., Lu S.H. Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res. 2007, 67:3716-3724.
8. Zhang Y., Peng J., Zhang H., Zhu Y., Wan L., Chen J., Chen X., Lin R., Li H., Mao X., Jin K. Notch1 signaling is activated in cells expressing embryonic stem cell proteins in human primary nasopharyngeal carcinoma. J. Otolaryngol. Head Neck Surg. 2010, 39:157-166.
9. Soltysova A., Altanerova V., Altaner C. Cancer stem cells. Neoplasma 2005, 52:435-440.
10. Kang M.K., Hur B.I., Ko M.H., Kim C.H., Cha S.H., Kang S.K. Potential identity of multi-potential cancer stem-like subpopulation after radiation of cultured brain glioma. BMC Neurosci. 2008, 9:15.
11. Lage H. An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol. Life Sci. 2008, 65:3145-3167.
12. Yuan T.L., Cantley L.C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27:5497-5510.
13. Yilmaz O.H., Valdez R., Theisen B.K., Guo W., Ferguson D.O., Wu H., Morrison S.J. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006, 441:475-482.
14. Hambardzumyan D., Becher O.J., Rosenblum M.K., Pandolfi P.P., Manova-Todorova K., Holland E.C. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev. 2008, 22:436-448.
15. Shanmugaratnam K., Sobin L.H. Histological Typing of Tumours of the Upper Respiratory Tract & Ear 1991, Springer-Verlag, New York. second ed.
16. Jin K., Sun Y., Xie L., Peel A., Mao X.O., Batteur S., Greenberg D.A. Directed migration of neuronal precursors into the ischemic cerebral cortex and striatum. Mol. Cell Neurosci. 2003, 24:171-189.
17. Jin K., Mao X., Sun Y., Xie L., Greenberg D. Stem cell factor stimulates neurogenesis in vitro and in vivo. J. Clin. Invest. 2002, 110:311-319.
18. Jin K., Mao X.O., Sun Y., Xie L., Jin L., Nishi E., Klagsbrun M., Greenberg D.A. Heparin-binding epidermal growth factor-like growth factor: hypoxia-inducible expression in vitro and stimulation of neurogenesis in vitro and in vivo. J. Neurosci. 2002, 22:5365-5373.
19. Engelman J.A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 2009, 9:550-562.
20. Bose S., Chandran S., Mirocha J.M., Bose N. The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod. Pathol. 2006, 19:238-245.
21. Chow S., Minden M.D., Hedley D.W. Constitutive phosphorylation of the S6 ribosomal protein via mTOR and ERK signaling in the peripheral blasts of acute leukemia patients. Exp. Hematol. 2006, 34:1183-1191.
22. Pantuck A.J., Seligson D.B., Klatte T., Yu H., Leppert J.T., Moore L., O'Toole T., Gibbons J., Belldegrun A.S., Figlin R.A. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007, 109:2257-2267.
23. Robb V.A., Karbowniczek M., Klein-Szanto A.J., Henske E.P. Activation of the mTOR signaling pathway in renal clear cell carcinoma. J. Urol. 2007, 177:346-352.
24. Cotler S.J., Hay N., Xie H., Chen M.L., Xu P.Z., Layden T.J., Guzman G. Immunohistochemical expression of components of the Akt-mTORC1 pathway is associated with hepatocellular carcinoma in patients with chronic liver disease. Dig. Dis. Sci. 2008, 53:844-849.
25. Iwenofu O.H., Lackman R.D., Staddon A.P., Goodwin D.G., Haupt H.M., Brooks J.S. Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy. Mod. Pathol. 2008, 21:231-237.
26. Trinh X.B., Tjalma W.A., Vermeulen P.B., Van den Eynden G., Van der Auwera I., Van Laere S.J., Helleman J., Berns E.M., Dirix L.Y., van Dam P.A. The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. Br. J. Cancer 2009, 100:971-978.
27. Huang X.M., Dai C.B., Mou Z.L., Wang L.J., Wen W.P., Lin S.G., Xu G., Li H.B. Overproduction of cyclin D1 is dependent on activated mTORC1 signal in nasopharyngeal carcinoma: implication for therapy. Cancer Lett. 2009, 279:47-56.
28. Shair K.H., Schnegg C.I., Raab-Traub N. EBV latent membrane protein 1 effects on plakoglobin, cell growth, and migration. Cancer Res. 2008, 68:6997-7005.
29. Yip W.K., Leong V.C., Abdullah M.A., Yusoff S., Seow H.F. Overexpression of phospho-Akt correlates with phosphorylation of EGF receptor, FKHR and BAD in nasopharyngeal carcinoma. Oncol. Rep. 2008, 19:319-328.
30. Ghayad S.E., Bieche I., Vendrell J.A., Keime C., Lidereau R., Dumontet C., Cohen P.A. MTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci. 2008, 99:1992-2003.
31. Taheri-Kadkhoda Z., Magnusson B., Svensson M., Mercke C., Bjork-Eriksson T. Expression modes and clinical manifestations of latent membrane protein 1, Ki-67, cyclin-B1, and epidermal growth factor receptor in nonendemic nasopharyngeal carcinoma. Head Neck 2009, 31:482-492.
32. Chua D.T., Nicholls J.M., Sham J.S., Au G.K. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2004, 59:11-20.
33. Horst D., Kriegl L., Engel J., Kirchner T., Jung A. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br. J. Cancer 2008, 99:1285-1289.
34. You H., Ding W., Rountree C.B. Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology 2010, 51:1635-1644.
35. Rodda D.J., Chew J.L., Lim L.H., Loh Y.H., Wang B., Ng H.H., Robson P. Transcriptional regulation of nanog by OCT4 and SOX2. J. Biol. Chem. 2005, 280:24731-24737.
36. Luo W., Li S., Peng B., Ye Y., Deng X., Yao K. Embryonic stem cells markers SOX2, OCT4 and Nanog expression and their correlations with epithelial-mesenchymal transition in nasopharyngeal carcinoma. PLoS One 2013, 8:e56324.
37. Zhou J., Wulfkuhle J., Zhang H., Gu P., Yang Y., Deng J., Margolick J.B., Liotta L.A., Petricoin E., Zhang Y. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc. Natl. Acad. Sci. USA 2007, 104:16158-16163.
38. Dubrovska A., Kim S., Salamone R.J., Walker J.R., Maira S.M., Garcia-Echeverria C., Schultz P.G., Reddy V.A. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc. Natl. Acad. Sci. USA 2009, 106:268-273.
39. Bleau A.M., Hambardzumyan D., Ozawa T., Fomchenko E.I., Huse J.T., Brennan C.W., Holland E.C. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009, 4:226-235.